#Bioretec #Finland #Tampere #RemeOs #biodegradable implants

Bioretec Ltd Modifies Shareholder Terms

Bioretec Ltd, a pioneer in biodegradable orthopedic implants, announced significant adjustments to its stock option programs on June 27, 2025. This decision comes after the company successfully completed a rights issue, where a total of 6,156,618 new shares were subscribed for. These new shares have officially been registered by the Finnish Patent and Registration Office, marking a pivotal moment for the company.

In accordance with the existing terms of the company’s stock option programs, the Board of Directors has resolved to adjust the subscription prices of new shares offered under these programs. The adjustments are meant to maintain fairness among all stakeholders, guaranteeing that holders of option rights are treated equally with other shareholders.

Purpose of Adjustments

The rationale behind these adjustments lies in the company's commitment to uphold equal treatment among its investors. With the recent share issuance potentially diluting existing holdings, it was crucial to modify the terms to reflect the new market conditions. By reducing the subscription prices of the various stock option programs, Bioretec ensures that option holders retain their proportional value relative to the increased number of shares.

New Subscription Prices

The new subscription prices for the various stock option programs are indicative of the ongoing strategic realignment at Bioretec:

• - 2018-1A, 2018-1B: Decreased from €1.50 to €1.42
• - 2018-1C, 2018-1D, 2020-1A: Reduced from €2.25 to €2.13
• - 2020-1B: Dropped from €3.00 to €2.84
• - 2020-1C: Adjusted from €3.75 to €3.55
• - 2023-1: Modified from €2.48 to €2.35
• - 2025-1, 2025-2: Lowered from €2.79 to €2.64

These changes illustrate Bioretec's proactive stance in protecting the interests of their stakeholders while adapting to evolving market dynamics.

About Bioretec

Founded in Finland, Bioretec operates on a global scale, focusing on the innovative use of biodegradable materials in orthopedic implants. The company claims a unique position in the medical device market, with its products currently used in about 40 different countries. Its flagship product line, RemeOs™, made from a magnesium alloy and hybrid composite, represents the forefront of technology aimed at improving surgical outcomes and providing efficient healthcare solutions. The implants developed by Bioretec are designed to be absorbed by the body - a revolutionary approach that eliminates the necessity for removal surgeries post-healing.

Future Prospects

Bioretec is anticipating a significant impact in the global orthopedic trauma and spine market, which exceeds USD 10 billion. By emphasizing innovations in fracture treatment and surgical procedures, Bioretec aims to set itself apart as an industry leader. The company received market authorization for its RemeOs™ product in the United States in March 2023, with European CE mark approval secured in January 2025, further solidifying their strategic market positioning.

“We believe that our advancements in biodegradable implants will not only improve healing rates but also provide better overall life quality for patients through streamlined surgical methods,” said the Interim CEO, Sarah van Hellenberg Hubar-Fisher.

Contact Information

For further inquiries, stakeholders can reach out to:

• - Sarah van Hellenberg Hubar-Fisher, Interim CEO - +31 6 1544 8736
• - Johanna Salko, CFO - +358 40 754 8172

The initiatives taken by Bioretec Ltd reflect a strong commitment to innovation and stakeholder equity, marking an exciting period for the company as it looks forward to substantial growth in the biomedical field.